Compare MAN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | VRDN |
|---|---|---|
| Founded | 1948 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1994 | 2014 |
| Metric | MAN | VRDN |
|---|---|---|
| Price | $30.40 | $13.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 14 |
| Target Price | ★ $35.67 | $35.46 |
| AVG Volume (30 Days) | 1.2M | ★ 3.5M |
| Earning Date | 04-16-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,957,100,000.00 | $5,706,000.00 |
| Revenue This Year | $5.12 | $13.73 |
| Revenue Next Year | $3.42 | $279.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.58 | N/A |
| 52 Week Low | $25.15 | $11.76 |
| 52 Week High | $47.34 | $34.29 |
| Indicator | MAN | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 23.57 |
| Support Level | $28.76 | $13.33 |
| Resistance Level | $30.40 | $18.95 |
| Average True Range (ATR) | 1.91 | 0.66 |
| MACD | 0.02 | 0.29 |
| Stochastic Oscillator | 60.43 | 7.67 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.